<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>Molecular Signalling</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C0A7056F-E319-488D-BC7B-EB4514B543F8"><gtr:id>C0A7056F-E319-488D-BC7B-EB4514B543F8</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Jonathan</gtr:otherNames><gtr:surname>Cook</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE02162X%2F1"><gtr:id>89D78667-7F75-44D7-9E03-980EED2830E3</gtr:id><gtr:title>How does ERK1/2-dependent phosphorylation target BimEL to the proteasome?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E02162X/1</gtr:grantReference><gtr:abstractText>The death of a cell sounds like a rather catastrophic event and so is perhaps most easily associated with disease. However, a special form of cell death, called apoptosis, is a perfectly normal part of our embryological development during which excess, unwanted cells are removed in a carefully controlled fashion. For example, the cells that form the webs between our fingers when we are in the womb are removed by apoptosis. Apoptosis is also important for the removal of diseased or damaged cells such as those with potentially cancer-causing gene mutations. Indeed, defects in this process of removing damaged cells can contribute to the development of cancer and auto-immunity. The fate of a cell, whether to die or not, is determined by the fine balance of pro-death and pro-survival proteins inside the cell. If pro-survival proteins accumulate to excess then cells can accumulate, resulting in developmental abnormalities or cancer. If pro-death proteins accumulate then too many cells die and this can again cause problems during development but can also contribute to diseases such as Alzheimer's dementia. These studies tell us that the abundance of pro-death or pro-survival proteins represents a key point of control. One such pro-death protein, called Bim, appears to be relatively important because genetically engineered mice that lack Bim have a hyper-active immune system (similar to auto-immunity) and can develop some forms of leukaemia, a type of a cancer of the blood cells. In both cases this is because cells don't die when they should do. The abundance of the Bim protein is an important point of control and there are mechanisms in place to make sure that Bim does not accumulate at the wrong time or place. In particular, survival signals inside the cell modify the Bim protein by attaching specific signals or 'flags' to it, thereby directing it for destruction. In this way the Bim protein is broken down into its constituent amino acids for recycling and the cell is protected from death. In this proposal, we want to understand the mechanism by which the Bim protein is 'flagged' for destruction. A specific enzyme allows the attachment of several copies of a small molecule called ubiquitin to Bim; this ubiquitin molecule acts as the 'flag', directing the Bim protein for destruction and protecting the cell from death. We want to identify the enzyme responsible for attachment of the ubiquitin flags to Bim for two reasons. First, because it is interesting in its own right as it will teach us much about how 'normal' cell death is controlled. Second, because Bim is an important pro-death molecule, the enzyme responsible for flagging Bim for destruction may contribute to cancer or auto-immunity, and so may teach us more about these diseases.</gtr:abstractText><gtr:technicalSummary>BimEL, a pro-apoptotic, BH3-only protein, must associate with pro-survival Bcl-2 proteins to kill cells. ERK1/2-dependent phosphorylation of BimEL targets the protein for ubiquitination and proteasomal degradation and is cyto-protective. The identity of the E3 ligase responsible for BimEL ubiquitination is not known, but one could postulate that it would bind in a phospho-specific manner to phosphorylated BimEL (Model 1). Our recent data has shown that the initial effect of ERK1/2 phosphorylation is to cause BimEL to separate from pro-survival proteins; this precedes, and is independent of, BimEL proteasomal degradation. This suggests a distinct model in which BimEL phosphorylation serves only to dissociate BimEL from pro-survival proteins, with the E3 ligase then binding in a non-phosphospecific fashion to a site exposed in unbound BimEL (Model 2). These two models predict E3 ligases with different properties whose identification will require different strategies. In this study we will identify the relationship between BimEL dissociation and degradation (Model 1 versus Model 2) and identify the minimal sequences of BimEL required for ERK1/2-dependent degradation (the BimEL degron) using site-directed mutagenesis, truncation analysis and biochemical assays in cells. This information will be used to identify the BimEL E3 ligase by a combination of strategies including testing of candidate proteins, affinity purification and proteomics, facilitated by substrate trapping ubiquitin mutants and, if appropriate, yeast 2-hybrid screening, should our analysis suggest that phosphorylation is not required for degradation after dissociation. Finally, we will validate the role of the E3 ligase in regulating BimEL ubiquitination in in vitro reconstitution assays and in vivo. If the E3 ligase is specific for BimEL then knock-down of its expression should increase in BimEL and induce Bim-dependent apoptosis; this will be tested in wild type and Bim-/- fibroblasts.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>354889</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D57F3EDB-DE4A-48D1-B562-D26F6F9C1A1E</gtr:id><gtr:impact>Students visited the lab and undertook small lab-based proejcts supervised by students/post-docs and myself. I explained the research that we do and discussed ethical issues such as the use of animals in research.
This precipitated excellent discussion and dialogue.

We received excellent feedback from the schools involved and requests for further outreach activities</gtr:impact><gtr:outcomeId>546f1146bc7243.35670753</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>We have shown that increases in BIM abundance are part of the mechanism by which new targeted anti-cancer drugs (kinase inhibitors) promote tumour cell death. This information is being used by the Pharma sector and clinicians</gtr:description><gtr:firstYearOfImpact>2007</gtr:firstYearOfImpact><gtr:id>D3E52792-0DBF-4DD1-998B-8886547183B1</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56e02a2f4eda55.16149479</gtr:outcomeId><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>BIM is a protein that drives cells to undergo a special form of cell death called apoptosis. It is normally kept in check by an enzyme called ERK - a protein kinase that phosphorylates BIM at several sites and thereby promotes its destruction within cells. We have shown that inhibition of ERK activity increases BIM abundance and thereby drives cells towards cell death. We have revealed new insights into how phosphorylation of the BIM protein results in its destruction</gtr:description><gtr:exploitationPathways>BIM operates to promote cell death in a variety of cell systems including the developing nervous system in the embryo and in the immune system. Understanding how BIM is regulated to promote cell death in these systems is vital for understanding how our bodies develop and stay healthy throughout our lifecourse. This knowledge may also be of use for pharmaceutical companies who want to promote cell death in cancer or reduce cell death in neurodegenerative disease</gtr:exploitationPathways><gtr:id>CD9FCFAB-65E6-40FA-991F-B3F4F0756FC6</gtr:id><gtr:outcomeId>56e0298bf08492.03702786</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>337DDEBE-C46F-4634-8110-DC878B86D73C</gtr:id><gtr:title>The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1 cell-cycle arrest and not a direct effect on BIK protein stability.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>546f505787e4e8.84425750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6FA7001-994D-4EDB-89A6-5EAA56D38E70</gtr:id><gtr:title>Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebcafe1f987cfead099a5f3e437b10c"><gtr:id>7ebcafe1f987cfead099a5f3e437b10c</gtr:id><gtr:otherNames>Wickenden JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56758af28397a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6102BFE3-311A-4C40-A781-E4E8BF6EC472</gtr:id><gtr:title>ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf6e6af50458bbc22d5aae1bf117b1fb"><gtr:id>bf6e6af50458bbc22d5aae1bf117b1fb</gtr:id><gtr:otherNames>Ewings KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>56dfe79f516704.12452607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0531026-F125-4ADD-A6A5-1B0788365DCB</gtr:id><gtr:title>Granulocyte/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bedc97eb00ae94b2e25c0b876eda4add"><gtr:id>bedc97eb00ae94b2e25c0b876eda4add</gtr:id><gtr:otherNames>Cowburn AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>56758dfb08b27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAF11FC5-F90D-48DE-957E-C9C6C5B5E7B4</gtr:id><gtr:title>Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b5e5c5f386db34fd8a812c9d0028f52"><gtr:id>2b5e5c5f386db34fd8a812c9d0028f52</gtr:id><gtr:otherNames>Paterson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>546f5108bece77.23647371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>603C056F-52CE-47BF-B3F1-9D29639E0304</gtr:id><gtr:title>Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf6e6af50458bbc22d5aae1bf117b1fb"><gtr:id>bf6e6af50458bbc22d5aae1bf117b1fb</gtr:id><gtr:otherNames>Ewings KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>56dfe79f320a53.39143421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1083BA2-9ABF-45CA-8EF3-68429DA078FA</gtr:id><gtr:title>That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>546f5057377115.23896403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C296DF38-B019-46D4-84AE-7E4D06962D1D</gtr:id><gtr:title>BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42c59dbfc698614694d0c06081ec05a"><gtr:id>f42c59dbfc698614694d0c06081ec05a</gtr:id><gtr:otherNames>Wiggins CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>56758ec937781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CA635F5-0045-4BF2-B5F5-E258E19059AA</gtr:id><gtr:title>CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>546f51089a20b5.37391864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480DE957-200E-4FBA-B051-7B28E24FA41A</gtr:id><gtr:title>The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>546f5057103fb2.10428686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>326D82DC-55B5-4DD7-9C71-4DFD3C1B8869</gtr:id><gtr:title>ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6729b387bf4e554c2fee167548dc24df"><gtr:id>6729b387bf4e554c2fee167548dc24df</gtr:id><gtr:otherNames>Darling NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa6aa1d4d76d9.20261673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F5B7A28-7195-44D2-8406-67883843DE45</gtr:id><gtr:title>Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d9a51fb590ce42722d2925380aa98f5"><gtr:id>3d9a51fb590ce42722d2925380aa98f5</gtr:id><gtr:otherNames>Cook SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5a2faee6dec678.71936775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A50D011-EFB0-4A4B-9F04-B9E878FF1DFE</gtr:id><gtr:title>Refining the minimal sequence required for ERK1/2-dependent poly-ubiquitination and proteasome-dependent turnover of BIM.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42c59dbfc698614694d0c06081ec05a"><gtr:id>f42c59dbfc698614694d0c06081ec05a</gtr:id><gtr:otherNames>Wiggins CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>56758cf6cd09c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD1AD846-D5D7-4E19-9E3B-D175B79C954D</gtr:id><gtr:title>c-Cbl is not required for ERK1/2-dependent degradation of BimEL.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42c59dbfc698614694d0c06081ec05a"><gtr:id>f42c59dbfc698614694d0c06081ec05a</gtr:id><gtr:otherNames>Wiggins CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>56dfe79ef339b6.44879443</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E02162X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>